Genomics Core
- Institution
- DANA-FARBER CANCER INST, MA
- Principal investigator
- Nikhil Wagle
- Funding
- $295K
- Duration
- 2010–2026
Moonbase score
Still being scored
Abstract
SUMMARY A critical gap often exists at lower resourced institutions between access to Genomics technologies and the high costs associated with required instrumentation, technical proficiency, and analytical expertise. The Genomics Core (GC) addresses this gap by providing expert and affordable access to high-throughput genomics technologies on a reduced fee basis for all Partnership investigators. The GC benefits the entire Partnership by providing innovative approaches to explore early project ideas, and by working with Partnership investigators and their trainees to facilitate the use of genomics technologies to build sustainable cancer biology research. To accomplish these goals, the GC (through the auspices of the Center for Personalized Cancer Therapy, CPCT) provides front-line genomics-related technologies, as well as bioinformatics support for data analysis, to Partnership investigators through an affordable reimbursement model. The GC proposes to accomplish these goals through the pursuit of four specific aims designed to build capacity for biomedical and cancer research and training at UMass Boston by bridging a gap in the availability of cutting-edge genomics-based tools; support Partnership investigators who wish to pursue early project ideas, especially those that require innovative and/or technically challenging genomics approaches; bridge a training gap between students and high-level genomics-based technologies, and provide bioinformatics analysis of data generated in the core.
LOADING MOONBASE SCORE
Questions for DANA-FARBER CANCER INST
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Broad Institute, Inc.Not yet scored
Administrative Core
Nikhil Wagle · $398K · 2020–2026
- NIH · Dana-Farber Cancer Inst51
HIV-1 Preintegration Trafficking and Nuclear Localization
Alan N. Engelman · $1.2M · 2003–2027
- NIH · Dana-Farber Cancer InstReviewed
Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial
Ting Bao · $661K · 2023–2025